--- title: "Types of Weight-Loss Injections Explained" description: "Compare Wegovy, Zepbound and Saxenda injections with diabetes brands, daily tablets and compounded preparations by ingredient, schedule and approved use." summary: "Wegovy, Zepbound and Saxenda are injection brands with weight-management indications. Ozempic and Mounjaro have diabetes indications. The ingredient, formulation and exact label matter when comparing treatment." canonical: https://remevihealth.com/blog/types-of-weight-loss-injections/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "Linda West-Conforti, RN" reviewStatus: current reviewedDate: 2026-09-22T00:00:00.000Z pubDate: 2026-06-01T00:00:00.000Z updatedDate: 2026-09-15T00:00:00.000Z tags: ["weight-loss injections","semaglutide","tirzepatide","GLP-1","liraglutide"] alternateLanguage: https://remevihealth.com/es/blog/tipos-de-inyecciones-para-bajar-de-peso/ license: "© 2026 REMEVi LLC. Please cite https://remevihealth.com/blog/types-of-weight-loss-injections/ as the source." --- ## Short answer Wegovy, Zepbound and Saxenda are injection brands with weight-management indications. Ozempic and Mounjaro have diabetes indications. The ingredient, formulation and exact label matter when comparing treatment. **Medically reviewed by** [Linda West-Conforti, RN](/medical-team/) · [CA RN #389453](https://search.dca.ca.gov/details/4500/RN/389453/) · 2026-09-22. Founding Nurse · Patient Care Lead. **Wegovy, Zepbound and Saxenda are three injection brands with U.S. weight-management indications.** They contain semaglutide, tirzepatide and liraglutide, respectively. The diabetes brands Ozempic and Mounjaro contain two of those ingredients but have different approvals. Start with the exact product and formulation, not a list of ingredient names. The comparison below focuses on these commonly discussed incretin medicines; it is not an exhaustive list of every injectable treatment or a REMEVi product catalog. ## Injection names, ingredients and approved uses | Injection | Ingredient and receptor action | Schedule | U.S. approved-use summary | |---|---|---|---| | Wegovy | Semaglutide; GLP-1 | Weekly | Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular-risk reduction in eligible adults; adult noncirrhotic MASH with F2–F3 fibrosis | | Zepbound | Tirzepatide; GIP and GLP-1 | Weekly | Adult weight management; moderate-to-severe obstructive sleep apnea in adults with obesity | | Saxenda | Liraglutide; GLP-1 | Daily | Weight management, including eligible adolescents 12+ with obesity and body weight over 60 kg | | Ozempic | Semaglutide; GLP-1 | Weekly | Adult type 2 diabetes; specified cardiovascular and kidney-risk indications in adults with type 2 diabetes | | Mounjaro | Tirzepatide; GIP and GLP-1 | Weekly | Type 2 diabetes in adults and children 10+; major cardiovascular-risk reduction in adults with type 2 diabetes at high risk | Sources: [Wegovy](https://www.novo-pi.com/wegovy.pdf), [Zepbound](https://pi.lilly.com/us/zepbound-uspi.pdf), [Saxenda](https://www.novo-pi.com/saxenda.pdf), [Ozempic injection](https://www.novo-pi.com/ozempic.pdf), [Mounjaro](https://pi.lilly.com/us/mounjaro-uspi.pdf), section 1 of each label. For adult weight management, the weight-management brands cover obesity or overweight with a weight-related condition, together with nutrition and physical activity changes. Wegovy's cardiovascular indication requires established cardiovascular disease and obesity or overweight. Its MASH indication is an accelerated approval for a specific liver condition; it is not a general liver-health claim. Pediatric approvals are product-specific and do not establish availability through REMEVi. See the [eligibility guide](/blog/glp1-eligibility-requirements/) for the difference between weight-management and diabetes criteria. ## What GLP-1 and GIP do GLP-1 receptor agonists affect appetite, slow stomach emptying and help regulate blood glucose. Their glucose-dependent action does not eliminate hypoglycemia risk, particularly when used with insulin or a sulfonylurea. Tirzepatide also activates GIP receptors. ![Illustration of the semaglutide molecule](/images/molecules/helix-sema.webp) *Semaglutide is a GLP-1 receptor agonist. A molecule illustration does not show a specific finished medication.* Two receptors do not establish that a treatment is best for everyone. The [tirzepatide mechanism guide](/blog/how-tirzepatide-works/) separates what the molecule does from what trials of specific products measured. ## Daily versus weekly is only one distinction All three weight-management injections begin with lower doses and increase according to their own labels. They do not share one escalation schedule or one missed-dose rule. A prescriber may need to reassess the dose after an interruption or significant side effects. A pen, prefilled syringe and vial can require different handling even within a brand. Get training for the actual presentation you receive. For a compounded vial, confirm the dose in mg, its concentration and the syringe marking with the pharmacy; “units” alone are not a medication dose. Read [semaglutide dosing and measurement](/blog/semaglutide-dosing-schedule/), [missed doses](/blog/missed-glp1-dose/) and [travel/storage](/blog/traveling-with-glp1-medication/). ## Are pills an alternative? Yes. Wegovy has daily tablets for adult weight management and cardiovascular-risk reduction in eligible adults. Its injection-only MASH and adolescent indications do not apply to the tablets. Ozempic also has tablets with diabetes-related indications. These oral products have different doses and cannot be substituted milligram for milligram. [Wegovy label](https://www.novo-pi.com/wegovy.pdf), [Ozempic tablet label](https://www.novo-pi.com/ozempictablets.pdf) Oral delivery does not by itself imply weak treatment, and injection does not guarantee a better result. Compare the actual medicine, administration requirements and evidence in [pills versus injections](/blog/weight-loss-pills-vs-injections/) and [Foundayo versus Wegovy pills](/blog/foundayo-vs-wegovy-pills/). ## Compounded preparations are a separate category A compounded semaglutide or tirzepatide preparation is not FDA-approved or a generic version of these brands. It cannot inherit their approved indications, dosing instructions or trial outcomes. Ask why the preparation meets a medical need that an available approved medicine cannot meet, and ask the pharmacy for product-specific instructions. [FDA: risks of compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs) ## How a clinician chooses The evaluation considers your diagnosis, medicines, past treatment, pregnancy plans, gastrointestinal symptoms and relevant risks. Personal or family medullary thyroid carcinoma, MEN2 and serious allergy to a product are among the contraindications listed for these medicines. Significant symptoms may require evaluation before treatment. REMEVi includes clinician-required GLP-1 labs; the clinician sets the tests and timing. Care is available in English and Spanish in 49 states and Washington, DC, excluding Louisiana. Review [lab testing](/blog/glp1-lab-tests/) and [current pricing](/pricing/) before your consultation. [See if you qualify](/quiz/). *Educational information, not medical advice. Product choice and eligibility require a licensed clinician; individual results vary.* ## Frequently asked questions ### What are the names of weight-loss injections? Wegovy contains semaglutide, Zepbound contains tirzepatide and Saxenda contains liraglutide. These brands have weight-management indications for specific populations. Ozempic and Mounjaro are different products with diabetes indications. ### How often are weight-loss injections given? Wegovy and Zepbound injections are weekly; Saxenda is daily. Each has its own dose-escalation instructions. A daily tablet or compounded preparation cannot use an injection's instructions by default. ### Are pills available instead of injections? Yes. Wegovy has an approved daily tablet for eligible adults, and other prescription oral options exist. Tablets have product-specific administration and eligibility rules; the route alone does not establish which treatment is more effective or appropriate. ### How does a clinician choose between semaglutide and tirzepatide? The clinician weighs the treatment indication, medical history, other medicines, tolerability and access. Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1. Receptor count does not decide which is right for a person. ## Sources linked in this article These are the external references linked in the article. A reference supports the statement where it appears; it is not an endorsement of REMEVi or a substitute for individual medical advice. - [Wegovy](https://www.novo-pi.com/wegovy.pdf) - [Zepbound](https://pi.lilly.com/us/zepbound-uspi.pdf) - [Saxenda](https://www.novo-pi.com/saxenda.pdf) - [Ozempic injection](https://www.novo-pi.com/ozempic.pdf) - [Mounjaro](https://pi.lilly.com/us/mounjaro-uspi.pdf) - [Ozempic tablet label](https://www.novo-pi.com/ozempictablets.pdf) - [FDA: risks of compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs) ## Related reading - [Weight-Loss Injections: Do You Need an Rx?](/blog/prescription-for-weight-loss-injections/) - [3 Questions to Ask Before Your First GLP-1 Dose](/blog/3-questions-before-first-glp1-dose/) - [Semaglutide vs. Tirzepatide: Differences, Results and Costs](/blog/semaglutide-vs-tirzepatide/) ## About this article Published by REMEVi, a telehealth business offering paid treatment programs. REMEVi has a commercial interest in the services discussed here. Educational content supports informed conversations with a licensed clinician; it does not determine your eligibility or replace individual care.